{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T06:58:36Z","timestamp":1778828316428,"version":"3.51.4"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003030","name":"Ag\u00e8ncia de Gesti\u00f3 d'Ajuts Universitaris i de Recerca","doi-asserted-by":"publisher","award":["2019 FI_B 00986"],"award-info":[{"award-number":["2019 FI_B 00986"]}],"id":[{"id":"10.13039\/501100003030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI095789, U01AI165745"],"award-info":[{"award-number":["R01AI095789, U01AI165745"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["2020-029886-I\/AEI\/10.13039\/501100011033"],"award-info":[{"award-number":["2020-029886-I\/AEI\/10.13039\/501100011033"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["PI11\/00423 and PI17\/02044"],"award-info":[{"award-number":["PI11\/00423 and PI17\/02044"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-025-01167-0","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T22:50:55Z","timestamp":1749163855000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Role of malaria exposure and off-target responses on RTS,S\/AS02A vaccine immunogenicity and protection in Mozambican children"],"prefix":"10.1038","volume":"10","author":[{"given":"Elisa","family":"Fuentes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenjerai","family":"Jairoce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Didac","family":"Maci\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonie","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge P.","family":"Torres-Yaguana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Vidal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebeca","family":"Santano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David L.","family":"Narum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Cavanagh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benoit","family":"Gamain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ross L.","family":"Coppel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James G.","family":"Beeson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheetij","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jahit","family":"Sacarlal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Aguilar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gemma","family":"Moncunill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlota","family":"Doba\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,6]]},"reference":[{"key":"1167_CR1","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/j.vaccine.2018.01.069","volume":"36","author":"CM Nielsen","year":"2018","unstructured":"Nielsen, C. M. et al. RTS,S malaria vaccine efficacy and immunogenicity during Plasmodium falciparum challenge is associated with HLA genotype. Vaccine 36, 1637\u20131642 (2018).","journal-title":"Vaccine"},{"key":"1167_CR2","first-page":"1065","volume":"6","author":"T Rutgers","year":"1988","unstructured":"Rutgers, T. et al. Hepatitis B surface antigen as carrier matrix for the repetitive epitope of the circumsporozoite protein of Plasmodium falciparum. Bio\/Technology6, 1065\u20131070 (1988).","journal-title":"Bio\/Technology"},{"key":"1167_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-015-0408-2","volume":"13","author":"MA Penny","year":"2015","unstructured":"Penny, M. A., Galactionova, K., Tarantino, M., Tanner, M. & Smith, T. A. The public health impact of malaria vaccine RTS,S in malaria endemic Africa: country-specific predictions using 18 month follow-up Phase III data and simulation models. BMC Med. 13, 170 (2015).","journal-title":"BMC Med."},{"key":"1167_CR4","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1016\/S0140-6736(24)00004-7","volume":"403","author":"KP Asante","year":"2024","unstructured":"Asante, K. P. et al. Feasibility, safety, and impact of the RTS,S\/AS01E malaria vaccine when implemented through national immunisation programmes: evaluation of cluster-randomised introduction of the vaccine in Ghana, Kenya, and Malawi. Lancet403, 1660\u20131670 (2024).","journal-title":"Lancet"},{"key":"1167_CR5","doi-asserted-by":"crossref","unstructured":"Chaudhury, S. et al. The biological function of antibodies induced by the RTS,S\/AS01 malaria vaccine candidate is determined by their fine specificity. Malaria J. https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-016-1348-9 (2016).","DOI":"10.1186\/s12936-016-1348-9"},{"key":"1167_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-018-1054-2","volume":"16","author":"L Kurtovic","year":"2018","unstructured":"Kurtovic, L. et al. Human antibodies activate complement against Plasmodium falciparum sporozoites, and are associated with protection against malaria in children. BMC Med. 16, 61 (2018).","journal-title":"BMC Med."},{"key":"1167_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-019-1277-x","volume":"17","author":"L Kurtovic","year":"2019","unstructured":"Kurtovic, L. et al. Induction and decay of functional complement-fixing antibodies by the RTS,S malaria vaccine in children, and a negative impact of malaria exposure. BMC Med. 17, 45 (2019).","journal-title":"BMC Med."},{"key":"1167_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02466-2","volume":"20","author":"G Feng","year":"2022","unstructured":"Feng, G. et al. Induction, decay, and determinants of functional antibodies following vaccination with the RTS,S malaria vaccine in young children. BMC Med. 20, 289 (2022).","journal-title":"BMC Med."},{"key":"1167_CR9","doi-asserted-by":"publisher","first-page":"eabb4757","DOI":"10.1126\/scitranslmed.abb4757","volume":"12","author":"TJ Suscovich","year":"2020","unstructured":"Suscovich, T. J. et al. Mapping functional humoral correlates of protection against malaria challenge following RTS,S\/AS01 vaccination. Sci. Transl. Med. 12, eabb4757 (2020).","journal-title":"Sci. Transl. Med."},{"key":"1167_CR10","doi-asserted-by":"publisher","first-page":"e00920","DOI":"10.1128\/IAI.00920-17","volume":"86","author":"MC Behet","year":"2018","unstructured":"Behet, M. C. et al. The complement system contributes to functional antibody-mediated responses induced by immunization with Plasmodium falciparum malaria sporozoites. Infect. Immun. 86, e00920\u201317 (2018).","journal-title":"Infect. Immun."},{"key":"1167_CR11","doi-asserted-by":"publisher","first-page":"7425","DOI":"10.1016\/j.vaccine.2015.09.061","volume":"33","author":"DC Kaslow","year":"2015","unstructured":"Kaslow, D. C. & Biernaux, S. RTS,S: toward a first landmark on the Malaria Vaccine Technology Roadmap. Vaccine 33, 7425\u20137432 (2015).","journal-title":"Vaccine"},{"key":"1167_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-018-1186-4","volume":"16","author":"I Ubillos","year":"2018","unstructured":"Ubillos, I. et al. Baseline exposure, antibody subclass, and hepatitis B response differentially affect malaria protective immunity following RTS,S\/AS01E vaccination in African children. BMC Med. 16, 197 (2018).","journal-title":"BMC Med."},{"key":"1167_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10195-z","volume":"10","author":"C Doba\u00f1o","year":"2019","unstructured":"Doba\u00f1o, C. et al. Concentration and avidity of antibodies to different circumsporozoite epitopes correlate with RTS,S\/AS01E malaria vaccine efficacy. Nat. Commun. 10, 2174 (2019).","journal-title":"Nat. Commun."},{"key":"1167_CR14","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1093\/infdis\/jiaa144","volume":"224","author":"L Kurtovic","year":"2021","unstructured":"Kurtovic, L. et al. Multifunctional antibodies are induced by the RTS,S malaria vaccine and associated with protection in a phase 1\/2a trial. J. Infect. Dis. 224, 1128\u20131138 (2021).","journal-title":"J. Infect. Dis."},{"key":"1167_CR15","doi-asserted-by":"crossref","unstructured":"Kurtovic, L. et al. Antibody mechanisms of protection against malaria in RTS,S-vaccinated children: a post-hoc serological analysis of phase 2 trial. Lancet Microbe 5, 100898 (2024).","DOI":"10.1016\/S2666-5247(24)00130-7"},{"key":"1167_CR16","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1084\/jem.20170869","volume":"215","author":"SW Scally","year":"2017","unstructured":"Scally, S. W. et al. Rare PfCSP C-terminal antibodies induced by live sporozoite vaccination are ineffective against malaria infection. J. Exp. Med. 215, 63\u201375 (2017).","journal-title":"J. Exp. Med."},{"key":"1167_CR17","doi-asserted-by":"crossref","unstructured":"Maci\u00e0, D. et al. Strong off-target antibody reactivity to malarial antigens induced by RTS,S\/AS01E vaccination is associated with protection. JCI Insight 7, e158030 (2022).","DOI":"10.1172\/jci.insight.158030"},{"key":"1167_CR18","doi-asserted-by":"crossref","unstructured":"Doba\u00f1o, C. et al. Differential patterns of IgG subclass responses to Plasmodium falciparum antigens in relation to malaria protection and RTS,S vaccination. Front. Immunol. https:\/\/www.frontiersin.org\/journals\/immunology\/articles\/10.3389\/fimmu.2019.00439\/full (2019).","DOI":"10.3389\/fimmu.2019.00439"},{"key":"1167_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-019-1378-6","volume":"17","author":"C Doba\u00f1o","year":"2019","unstructured":"Doba\u00f1o, C. et al. RTS,S\/AS01E immunization increases antibody responses to vaccine-unrelated Plasmodium falciparum antigens associated with protection against clinical malaria in African children: a case-control study. BMC Med. 17, 157 (2019).","journal-title":"BMC Med."},{"key":"1167_CR20","doi-asserted-by":"publisher","first-page":"6059","DOI":"10.1016\/j.vaccine.2011.03.041","volume":"29","author":"P Aide","year":"2011","unstructured":"Aide, P. et al. Four year immunogenicity of the RTS,S\/AS02A malaria vaccine in Mozambican children during a phase IIb trial. Vaccine 29, 6059\u20136067 (2011).","journal-title":"Vaccine"},{"key":"1167_CR21","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1056\/NEJMoa1207564","volume":"368","author":"A Olotu","year":"2013","unstructured":"Olotu, A. et al. Four-year efficacy of RTS,S\/AS01E and its interaction with malaria exposure. N. Engl. J. Med. 368, 1111\u20131120 (2013).","journal-title":"N. Engl. J. Med."},{"key":"1167_CR22","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1056\/NEJMoa1208394","volume":"367","author":"RTS,S Clinical Trials Partnership","year":"2012","unstructured":"RTS,S Clinical Trials Partnership et al. A phase 3 trial of RTS,S\/AS01 malaria vaccine in African infants. N. Engl. J. Med. 367, 2284\u20132295 (2012).","journal-title":"N. Engl. J. Med."},{"key":"1167_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00527-9","author":"D Maci\u00e0","year":"2024","unstructured":"Maci\u00e0, D. et al. The effect of Plasmodium falciparum exposure and maternal anti-circumsporozoite protein antibodies on responses to RTS,S\/AS01E vaccination in infants and children: an ancillary observational immunological study to a phase 3, randomised clinical trial. Lancet Infect. Dis. https:\/\/doi.org\/10.1016\/S1473-3099(24)00527-9 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"1167_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-014-0117-2","volume":"12","author":"MT White","year":"2014","unstructured":"White, M. T. et al. A combined analysis of immunogenicity, antibody kinetics and vaccine efficacy from phase 2 trials of the RTS,S malaria vaccine. BMC Med. 12, 117 (2014).","journal-title":"BMC Med."},{"key":"1167_CR25","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1016\/S0140-6736(04)17223-1","volume":"364","author":"PL Alonso","year":"2004","unstructured":"Alonso, P. L. et al. Efficacy of the RTS,S\/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 364, 1411\u20131420 (2004).","journal-title":"Lancet"},{"key":"1167_CR26","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1016\/j.vaccine.2014.02.042","volume":"32","author":"JJ Campo","year":"2014","unstructured":"Campo, J. J. et al. Duration of vaccine efficacy against malaria: 5th year of follow-up in children vaccinated with RTS,S\/AS02 in Mozambique. Vaccine 32, 2209\u20132216 (2014).","journal-title":"Vaccine"},{"key":"1167_CR27","doi-asserted-by":"publisher","first-page":"e5165","DOI":"10.1371\/journal.pone.0005165","volume":"4","author":"C Guinovart","year":"2009","unstructured":"Guinovart, C. et al. Insights into long-lasting protection induced by RTS,S\/AS02A malaria vaccine: further results from a phase IIb trial in Mozambican children. PLoS ONE 4, e5165 (2009).","journal-title":"PLoS ONE"},{"key":"1167_CR28","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1074\/mcp.M114.044677","volume":"14","author":"JJ Campo","year":"2015","unstructured":"Campo, J. J. et al. RTS,S vaccination is associated with serologic evidence of decreased exposure to Plasmodium falciparum liver- and blood-stage parasites. Mol. Cell. Proteom. 14, 519\u2013531 (2015).","journal-title":"Mol. Cell. Proteom."},{"key":"1167_CR29","doi-asserted-by":"publisher","first-page":"e25779","DOI":"10.1371\/journal.pone.0025779","volume":"6","author":"JJ Campo","year":"2011","unstructured":"Campo, J. J. et al. Impact of the RTS,S malaria vaccine candidate on naturally acquired antibody responses to multiple asexual blood stage antigens. PLoS ONE 6, e25779 (2011).","journal-title":"PLoS ONE"},{"key":"1167_CR30","doi-asserted-by":"publisher","first-page":"42","DOI":"10.12688\/wellcomeopenres.15002.1","volume":"4","author":"FM Ndungu","year":"2019","unstructured":"Ndungu, F. M. et al. A seven-year study on the effect of the pre-erythrocytic malaria vaccine candidate RTS,S\/AS01 E on blood stage immunity in young Kenyan children. Wellcome Open Res. 4, 42 (2019).","journal-title":"Wellcome Open Res."},{"key":"1167_CR31","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.4049\/jimmunol.1701010","volume":"200","author":"JE Schrum","year":"2018","unstructured":"Schrum, J. E. et al. Cutting Edge: Plasmodium falciparum induces trained innate immunity. J. Immunol. 200, 1243\u20131248 (2018).","journal-title":"J. Immunol."},{"key":"1167_CR32","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1056\/NEJMoa2034031","volume":"385","author":"MR Gaudinski","year":"2021","unstructured":"Gaudinski, M. R. et al. A monoclonal antibody for malaria prevention. N. Engl. J. Med. 385, 803\u2013814 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1167_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-13-608","volume":"13","author":"MM Medeiros","year":"2013","unstructured":"Medeiros, M. M. et al. Natural antibody response to Plasmodium falciparum merozoite antigens MSP5, MSP9 and EBA175 is associated to clinical protection in the Brazilian Amazon. BMC Infect. Dis. 13, 608 (2013).","journal-title":"BMC Infect. Dis."},{"key":"1167_CR34","doi-asserted-by":"publisher","first-page":"e101737","DOI":"10.1371\/journal.pone.0101737","volume":"9","author":"R Perraut","year":"2014","unstructured":"Perraut, R. et al. Association of antibody responses to the conserved Plasmodium falciparum merozoite surface protein 5 with protection against clinical malaria. PLoS ONE 9, e101737 (2014).","journal-title":"PLoS ONE"},{"key":"1167_CR35","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/76272","volume":"6","author":"DJ Conway","year":"2000","unstructured":"Conway, D. J. et al. A principal target of human immunity to malaria identified by molecular population genetic and immunological analyses. Nat. Med. 6, 689\u2013692 (2000).","journal-title":"Nat. Med."},{"key":"1167_CR36","doi-asserted-by":"crossref","unstructured":"Tham, W.-H. et al. Antibodies to reticulocyte binding protein-like homologue 4 inhibit invasion of Plasmodium falciparum into human erythrocytes. Infect. Immun. https:\/\/journals.asm.org\/doi\/10.1128\/iai.00048-09 (2009).","DOI":"10.1128\/IAI.00048-09"},{"key":"1167_CR37","doi-asserted-by":"crossref","unstructured":"Reiling, L. et al. The Plasmodium falciparum erythrocyte invasion ligand Pfrh4 as a target of functional and protective human antibodies against malaria. PLoS ONE. https:\/\/journals.plos.org\/plosone\/article?id=10.1371\/journal.pone.0045253 (2012).","DOI":"10.1371\/journal.pone.0045253"},{"key":"1167_CR38","doi-asserted-by":"publisher","first-page":"e17454","DOI":"10.15252\/emmm.202317454","volume":"15","author":"OE Oludada","year":"2023","unstructured":"Oludada, O. E. et al. Molecular and functional properties of human Plasmodium falciparum CSP C-terminus antibodies. EMBO Mol. Med. 15, e17454 (2023).","journal-title":"EMBO Mol. Med."},{"key":"1167_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms1615","volume":"2","author":"AD Douglas","year":"2011","unstructured":"Douglas, A. D. et al. The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody. Nat. Commun. 2, 601 (2011).","journal-title":"Nat. Commun."},{"key":"1167_CR40","doi-asserted-by":"publisher","first-page":"245","DOI":"10.4049\/jimmunol.1302045","volume":"192","author":"AD Douglas","year":"2014","unstructured":"Douglas, A. D. et al. Neutralization of Plasmodium falciparum merozoites by antibodies against PfRH5. J. Immunol. 192, 245\u2013258 (2014).","journal-title":"J. Immunol."},{"key":"1167_CR41","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1128\/IAI.00970-13","volume":"82","author":"KS Reddy","year":"2014","unstructured":"Reddy, K. S. et al. Bacterially expressed full-length recombinant Plasmodium falciparum RH5 protein binds erythrocytes and elicits potent strain-transcending parasite-neutralizing antibodies. Infect. Immun. 82, 152\u2013164 (2014).","journal-title":"Infect. Immun."},{"key":"1167_CR42","doi-asserted-by":"publisher","first-page":"338","DOI":"10.4269\/ajtmh.17-1014","volume":"99","author":"SA Jongo","year":"2018","unstructured":"Jongo, S. A. et al. Safety, immunogenicity, and protective efficacy against controlled human malaria infection of Plasmodium falciparum sporozoite vaccine in Tanzanian adults. Am. J. Trop. Med. Hyg. 99, 338\u2013349 (2018).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"1167_CR43","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1172\/JCI75429","volume":"124","author":"E Muyanja","year":"2014","unstructured":"Muyanja, E. et al. Immune activation alters cellular and humoral responses to yellow fever 17D vaccine. J. Clin. Invest. 124, 3147\u20133158 (2014).","journal-title":"J. Clin. Invest."},{"key":"1167_CR44","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0140-6736(23)02511-4","volume":"403","author":"MS Datoo","year":"2024","unstructured":"Datoo, M. S. et al. Safety and efficacy of malaria vaccine candidate R21\/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial. Lancet 403, 533\u2013544 (2024).","journal-title":"Lancet"},{"key":"1167_CR45","doi-asserted-by":"crossref","unstructured":"Jongo, S. A. et al. Safety and immunogenicity of radiation-attenuated PfSPZ vaccine in Equatoguinean infants, children, and adults. Am. J. Trop. Med. Hyg. 109, 138\u2013146 (2023).","DOI":"10.4269\/ajtmh.22-0773"},{"key":"1167_CR46","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1093\/cid\/ciz925","volume":"71","author":"LC Steinhardt","year":"2020","unstructured":"Steinhardt, L. C. et al. Safety, tolerability, and immunogenicity of Plasmodium falciparum sporozoite vaccine administered by direct venous inoculation to infants and young children: findings from an age de-escalation, dose-escalation, double-blind, randomized controlled study in western Kenya. Clin. Infect. Dis. 71, 1063\u20131071 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"1167_CR47","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/S1473-3099(24)00179-8","volume":"24","author":"M Juraska","year":"2024","unstructured":"Juraska, M. et al. Genotypic analysis of RTS,S\/AS01E malaria vaccine efficacy against parasite infection as a function of dosage regimen and baseline malaria infection status in children aged 5\u201317 months in Ghana and Kenya: a longitudinal phase 2b randomised controlled trial. Lancet Infect. Dis. 24, 1025\u20131036 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"1167_CR48","doi-asserted-by":"publisher","first-page":"4473","DOI":"10.1016\/S0264-410X(01)00207-9","volume":"19","author":"M Ceyhan","year":"2001","unstructured":"Ceyhan, M., Kanra, G., Erdem, G. & Kanra, B. Immunogenicity and efficacy of one dose measles\u2013mumps\u2013rubella (MMR) vaccine at twelve months of age as compared to monovalent measles vaccination at nine months followed by MMR revaccination at fifteen months of age. Vaccine 19, 4473\u20134478 (2001).","journal-title":"Vaccine"},{"key":"1167_CR49","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1097\/INF.0b013e318060d33d","volume":"26","author":"JL Silber","year":"2007","unstructured":"Silber, J. L., Chan, I. S. F., Wang, W. W., Matthews, H. & Kuter, B. J. Immunogenicity of Oka\/Merck varicella vaccine in children vaccinated at 12\u201314 months of age versus 15\u201323 months of age. Pediatr. Infect. Dis. J. 26, 572 (2007).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"1167_CR50","unstructured":"Malaria Atlas Project. Global Plasmodium falciparum Incidence Rate map. Available from: https:\/\/data.malariaatlas.org\/maps?layers=Malaria:202406_Global_Pf_Parasite_Rate&extent (2024)."},{"key":"1167_CR51","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1016\/S0140-6736(05)67669-6","volume":"366","author":"PL Alonso","year":"2005","unstructured":"Alonso, P. L. et al. Duration of protection with RTS,S\/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet 366, 2012\u20132018 (2005).","journal-title":"Lancet"},{"key":"1167_CR52","doi-asserted-by":"publisher","first-page":"e0199278","DOI":"10.1371\/journal.pone.0199278","volume":"13","author":"I Ubillos","year":"2018","unstructured":"Ubillos, I. et al. Analysis of factors affecting the variability of a quantitative suspension bead array assay measuring IgG to multiple Plasmodium antigens. PLoS ONE 13, e0199278 (2018).","journal-title":"PLoS ONE"},{"key":"1167_CR53","unstructured":"Therneau, T. A package for survival analysis in R. Available from: https:\/\/CRAN.R-project.org\/package=survival (2024)."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01167-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01167-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01167-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T11:03:27Z","timestamp":1749207807000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01167-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,6]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1167"],"URL":"https:\/\/doi.org\/10.1038\/s41541-025-01167-0","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,6]]},"assertion":[{"value":"22 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"116"}}